Contact

Biologics US 2024

3 - 4 October 2024 | San Diego, CA

Driving the discovery & development of safe, effective & innovative biologic drugs through streamlined discovery, clinical and analytical strategies

Event Page - Hero Banner 2
Overview Proteins & Antibodies Peptides ADC Discovery & Development

Explore Biologics US 2024: Overcoming the Complexities of Biologics Development

Biologics have come to the forefront of the pharmaceutical industry, with ever-increasing demand for large molecule products, but their development still presents unique and complex challenges from both technical and regulatory perspectives. Join 550+ leaders from across the US biologics industry at Biologics US to discuss the innovative strategies & technologies needed to enable more effective biological products to enter the market. 

Across two days, it features novel case studies from all corners of the biologics industry, with dedicated programmes covering next-generation Protein & Antibody Therapeutics, Peptides, and Antibody-Drug Conjugates. Alongside innovative presentations, our curated programme allows for in-depth networking – fostering new partnerships that will advance your pipeline and help you translate your innovative target from bench to bedside.

Download Agenda

Proteins & Antibodies US Congress 2024

From new engineering technologies and AI/ML-guided approaches through to novel analytical development methods and success stories in NextGen therapeutics, the Proteins & Antibodies US Congress provides an all-encompassing look at the back-bone of the biologics industry.

Agenda at a Glance

Day One | Track 1: Antibody Discovery & Engineering

Day One | Track 2: Bioanalytical Development

Day Two | Track 1: Computational Tools, AI/ML-Guided Engineering

Day Two | Track 2: NextGen Therapeutics – Multispecifics, Cell Engagers, & Other New Modalities

Download Agenda

Peptides US Congress 2024

Peptide drug development has made huge progress in the last decade, with advancements in production, modification and analytical technologies. With this rise in investment and innovation continuing to increase, our dedicated Peptides Congress showcases novel data in peptide CMC, delivery and drug development, supporting you as you look to optimize complex molecules.

Agenda at a Glance

Day One | Track 3: Peptide Discovery & Development

Day Two | Track 3: Peptide Formulation, Delivery & Manufacturing

Download Agenda

ADC Discovery & Development US Congress

2023 proved to be a monumental year for the ADCs industry, with high-profile collaborations between biopharma organizations and innovative new molecules reaching the clinic. The ADC Discovery & Development Congress seeks to advance ADC development further by maximizing efficiency and minimizing toxicity through safe, effective and streamline preclinical, clinical and CMC strategies. Further sessions look at the next-generation of conjugates, showcasing new approaches that could tackle different disease areas where there is currently unmet need.

Agenda at a Glance

Day One | Track 4: Engineering Conjugates to Enhance Therapeutic Potential

Day One | Track 5: Advancing Analytical Methods

Day Two | Track 4: Translational & Clinical Lessons

Day Two | Track 5: Manufacturing, CMC & Process Development 

Download Agenda

What to Expect

500

leading pharma, biotech & academic delegates

35
hours of presentations, discussions & interactive content
11
hours of networking breaks, including speed networking & refreshments
70
hours of pre-arranged 1-2-1 meetings, facilitating business growth
Interactive Presentations
Exhibition Hall
Networking Drinks
Poster Display
Event App Swapcard

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of experiences

  • Engaging Thought Leadership

    Over 120 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts

  • Global Technological Showcase

    An international exhibition showcasing cutting-edge technologies and services from leading providers in the scientific field.

  • Networking Emphasis

    Unparalleled networking opportunities, including speed networking sessions, a vibrant drinks reception, and informal gatherings to foster meaningful connections

  • Innovative Poster Displays

    Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and academic institutions

Companies Represented Include

Meet Our Expert Speakers

Biologics US 2024 again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.

Below are some of our featured speakers:

Brittney Mills
Associate Director,
AbbVie
Natalie Grinshtein
Director, ADC discovery,
Pfizer
Robert Lutz
CSO,
Iksuda Therapeutics
Suk Hyung
Senior Principal Scientist,
Genentech
Show More Speakers
Hide Speakers

All Speakers

Aming Zhang
Senior Director, Head of Analytical Development and QC,
Pyxis Oncology
Amita Datta-Mannan
Associate Vice President, Exploratory Medicine and Pharmacology,
Eli Lilly & Company
Andrew Vendel
Senior Director, Immunology,
Eli Lilly
Brandon Coyle
Senior Research Scientist II,
Gilead Sciences
Christopher Hart
Chief Executive Officer,
Creyon Bio
Feng Wang
Director / Senior Principal Scientist,
Genentech
Hans van der Vliet
CSO,
LAVA Therapeutics
Jack Ostrowski
Director Protein Science,
Avidity Biosciences
Jan Schnitzer
Chief Executive Officer & President,
PRISM
Jay Jones
Scientist,
Pfizer
Jean Ge
Patent Attorney,
Wolf Greenfield
Jeffrey Leyton
Associate Professor,
University of Ottawa
Julie Beaudet
CMC Sr. Staff Scientist,
Regeneron Pharmaceuticals
Leonard Reyno
Executive Vice President & Chief Medical Officer,
C4 Therapeutics
Li Feng
Partner,
Finnegan
Lian Yi
Principal Scientist,
Genentech
Linda Horner
Chief Administrative Patent Judge,
United States Patent and Trademark Office
Madhura Deshpande
Principal Scientist,
Bristol Myers Squibb
Maria Hedlund
Principal Scientist, Toxicology,
Avidity Biosciences
Matt Chu
Director,
Astellas Pharma US
Melissa Schutten
Senior Director, Head of Pathology,
Seagen
Michael Cochran
Director, Chemistry,
Avidity Biosciences
Michael McPherson
Research Fellow,
AbbVie
Mike Schopperle
CEO,
CureMeta
Nathan Alves
Associate Professor / Director of Translational Research,
Indiana University School of Medicine
Nazneen Dewji
President and Chief Executive Officer,
Cenna Biosciences
Norbert Furtmann
Head of AI Innovation NANOBODY® Platform & Group Head Computational & High-throughput Protein Engineering,
Sanofi
Olivier Kitten
Founder and Chief Executive Officer,
Affilogic
Purbasa Patnaik
Associate Director,
Exelixis
Ramana Doppalapudi
Vice President, Chemistry,
Avidity Biosciences
Rob Hughes
Senior Director, Pharmaceutical Sciences,
Cidara Therapeutics
Sasha Ebrahimi
Principal Investigator and Associate Fellow,
GSK
Steven Ballet
Professor, Departments of Chemistry and Bio-Engineering Sciences,
Free University Brussels
Sylvia Yip
Intellectual Property Counsel,
Zentalis Pharmaceuticals
Yang Su
Principal Scientist,
Bristol Myers Squibb
Yuan Cheng
Director of Hybrid Modality,
Amgen

Interested in Sponsoring?

Oxford Global’s range of sponsorship opportunities are highly effective in enabling market immersion and visibility, with direct access to clients and potential customers.

Learn more

Latest Resources

Merus's Preclinical Bispecific Zeno Demonstrates Efficacy in Cancer Models

Zeno interrupts the dimerization of HER2 and HER3 and prevents NRG1/HER3 tumour signalling.
Read More

New peptide with hope of treating triple-negative breast cancer

The preclinical peptide could unlock much needed treatment options for patients with triple-negative breast cancer.
Read More

Overcoming the Hurdles: Navigating the Challenges of Bioconjugate Development

Bioconjugate development, exemplified by ADCs such as T-DM1 and Mylotarg, tackles issues like stability and specificity, benefiting from innovative solutions and services to enhance therapeutic precision in biologics.
Read More

The Current Landscape of ADC Approvals and Market Trends: Q&A With Mahendra Deonarain, CEO of Antikor Biopharma

While a recent spike in ADC approvals may not last forever, Antikor Biopharma’s Mahendra Deonarain asserts that antibody-drug conjugates are here to stay.
Read More

Sustainable Pharma: Celebrating Progress and Confronting Challenges on Earth Day

Earth Day marks a moment to reflect on the planet's health and our collective efforts to nurture it. To celebrate Earth Day, this article will examine the strides the pharmaceutical and biotechnology industry has made towards fostering sustainable and green practices alongside the challenges.
Read More

Rapid Analytical Approach for Biologics Characterization Using Mass Photometry

On-demand webinar featuring Dr Racha Majed, Technical Sales Specialist, Refeyn
Read More

Plan Your Visit

Information regarding accommodation for this event will be added soon

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Biologics US 2024 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Register Your Interest

Submit your details and a member of our team will be in touch